← Leaderboards
Xiaoguang Margaret Liu
University Of Alabama At Birmingham
$3,757,363
Attributed
$9,028,691
Total exposure
7
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2020–25$2.5M$1.9M$1.3M$625K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,028,691 · 7
By mechanism
R01$8,042,905 · 4
R21$742,642 · 2
R43$243,144 · 1
Top collaborators
- Runhua Runa Liu11 shared
- Lizhong Wang5 shared
- Renata Jaskula-Sztul4 shared
- Eddy Yang4 shared
- Lufang Zhou4 shared
- William E. Carson3 shared
- Sadanandan E. Velu2 shared
- Joseph N Garner1 shared
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Runhua Runa Liu$2,517,658
- Renata Jaskula-Sztul$501,522
- Sadanandan E. Velu$941,686
- Upender Manne$11,389,346
- Kai Jiao$7,147,323
Others in their field
Other Emerging Leaders on “Monoclonal Antibodies”
- Bambra Strokes · Ppd Development Lp$461,655,950
- Yunda Huang · Fred Hutchinson Cancer Center$72,724,451
- Wendy Sammons-Jackson · National Institute Of Allergy And Infectious Diseases$27,369,420
- Arnab Kumar Chatterjee · Washington University$22,541,385
- Julie Ake · National Institute Of Allergy And Infectious Diseases$22,000,000
- Timothy Fouts · Advanced Bioscience Laboratories, Inc.$20,284,295
Research focus
Monoclonal AntibodiesAnti-CancerTargeted TreatmentIn VivoBiodistributionInvestigationSpecificitySystemic ToxicityXenograft ModelTumorSurvival RateXenograft ProcedureDosageMediatingSurfacePre-Clinical ModelOverexpressionChemotherapyPharmaceutical PreparationsIn VitroOperative Surgical ProceduresPre-ClinicalBreast Cancer CellEvaluation
Grant awards (23)
Dual-payload antibody-drug conjugate for chemo-immunotherapy of triple-negative breast cancers$575,907
R01 · FY2025 · CA · contact PI
Combine mitochondrial gene therapy and synthetic lethal chemotherapy to treat triple-negative breast cancer$573,078
R01 · FY2025 · CA · contact PI
Synergistic Targeted Therapy of Antibody-Drug Conjugates for Triple-Negative Breast Cancer$85,364
R01 · FY2025 · CA
Dual-payload antibody-drug conjugate for chemo-immunotherapy of triple-negative breast cancers$553,091
R01 · FY2024 · CA · contact PI
Combine mitochondrial gene therapy and synthetic lethal chemotherapy to treat triple-negative breast cancer$544,425
R01 · FY2024 · CA · contact PI
Synergistic Targeted Therapy of Antibody-Drug Conjugates for Triple-Negative Breast Cancer$462,863
R01 · FY2024 · CA
Identifying a New Biological Target for Breast Cancer Therapy That Contributes to Disparities for African-American Women$322,710
R01 · FY2024 · CA
Dual-payload antibody-drug conjugate for chemo-immunotherapy of triple-negative breast cancers$587,169
R01 · FY2023 · CA · contact PI
Combine mitochondrial gene therapy and synthetic lethal chemotherapy to treat triple-negative breast cancer$561,617
R01 · FY2023 · CA · contact PI
Synergistic Targeted Therapy of Antibody-Drug Conjugates for Triple-Negative Breast Cancer$477,479
R01 · FY2023 · CA
Identifying a New Biological Target for Breast Cancer Therapy That Contributes to Disparities for African-American Women$332,900
R01 · FY2023 · CA
Targeted neuroendocrine cancer therapy using Verrucarin A$170,089
R21 · FY2023 · CA
Combine mitochondrial gene therapy and synthetic lethal chemotherapy to treat triple-negative breast cancer$587,453
R01 · FY2022 · CA · contact PI
Synergistic Targeted Therapy of Antibody-Drug Conjugates for Triple-Negative Breast Cancer$477,479
R01 · FY2022 · CA
Identifying a New Biological Target for Breast Cancer Therapy That Contributes to Disparities for African-American Women$332,900
R01 · FY2022 · CA
Targeted neuroendocrine cancer therapy using Verrucarin A$208,271
R21 · FY2022 · CA
Synergistic Targeted Therapy of Antibody-Drug Conjugates for Triple-Negative Breast Cancer$401,859
R01 · FY2021 · CA
Identifying a New Biological Target for Breast Cancer Therapy That Contributes to Disparities for African-American Women$339,694
R01 · FY2021 · CA
Somatostatin receptor 2 (SSTR2) antibody-drug conjugate for pancreatic neuroendocrine tumor (PanNET) therapy$164,785
R21 · FY2021 · CA
Synergistic Targeted Therapy of Antibody-Drug Conjugates for Triple-Negative Breast Cancer$487,223
R01 · FY2020 · CA
Identifying a New Biological Target for Breast Cancer Therapy That Contributes to Disparities for African-American Women$339,694
R01 · FY2020 · CA
Targeted Exosome-Associated AAV-Mediated Gene Therapy to Eliminate Metastatic Neuroendocrine Cancers$243,144
R43 · FY2020 · CA
Somatostatin receptor 2 (SSTR2) antibody-drug conjugate for pancreatic neuroendocrine tumor (PanNET) therapy$199,497
R21 · FY2020 · CA